Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in Interest ReceivablesChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Prokidney (PROK) Gains from Sales and Divestitures: 2022-2025

Historic Gains from Sales and Divestitures for Prokidney (PROK) over the last 3 years, with Sep 2025 value amounting to $959,764.

  • Prokidney's Gains from Sales and Divestitures fell 28.19% to $959,764 in Q3 2025 from the same period last year, while for Sep 2025 it was $959,764, marking a year-over-year decrease of 28.19%. This contributed to the annual value of $1.3 million for FY2024, which is 41.02% down from last year.
  • As of Q3 2025, Prokidney's Gains from Sales and Divestitures stood at $959,764, which was down 0.00% from $959,764 recorded in Q2 2025.
  • Prokidney's 5-year Gains from Sales and Divestitures high stood at $2.3 million for Q3 2023, and its period low was $949,678 during Q1 2025.
  • In the last 3 years, Prokidney's Gains from Sales and Divestitures had a median value of $1.3 million in 2024 and averaged $1.5 million.
  • Per our database at Business Quant, Prokidney's Gains from Sales and Divestitures soared by 65.89% in 2023 and then slumped by 41.55% in 2024.
  • Quarterly analysis of 4 years shows Prokidney's Gains from Sales and Divestitures stood at $1.7 million in 2022, then surged by 30.67% to $2.3 million in 2023, then slumped by 41.02% to $1.3 million in 2024, then dropped by 28.19% to $959,764 in 2025.
  • Its last three reported values are $959,764 in Q3 2025, $959,764 for Q2 2025, and $949,678 during Q1 2025.